Background: PCV13 introduction in China has led to a significant reduction of vaccine serotype . However, non-vaccine serotypes with highly resistance and invasiveness were often reported in the post-pneumococcal conjugate vaccine era and there was regional differences.

Methods: A total of 669 strains were collected from the respiratory tracts of hospitalized children at Shenzhen Children's Hospital in 2021 and 2022. Antimicrobial resistance (AMR) characteristics were assessed through antibiotic susceptibility testing performed with the VITEK 2 compact system. AMR genes and single nucleotide polymorphisms (SNPs) in pbp1a, pbp2b, and pbp2x were identified via analysis of whole genome sequencing data. Statistical examination of the data was conducted employing chi-square and Fisher's exact tests.

Results: We found that non-vaccine serotypes strains had accounted for 46.6% of all the pneumococcal isolated strains. The most common non-vaccine serotype is 23A, with a prevalence rate of 8.9%, followed by 15A (6.6%), 6E (5.7%), 34 (3.2%), and 15B (2.9%). The multidrug resistance rates (MDR) of vaccine serotypes were 19F (99.36%), 19A (100%), 23F (98.08%), 6B (100%), and 6C (100%). Meanwhile, the MDR of non-vaccine serotypes were 15B (100.00%), 6E (100%), 15C (100%), 34 (95.24%), and 23A (98.31%). Resistance rates of 6E to more than six antibiotic classes reached 89.47%, which is similar to 19F (83.33%) and 19A (90%). Unique resistance profiles were also identified for non-vaccine serotypes, including significantly higher resistance to chloramphenicol in 6E, 15B, and 15C than in 19F and 19A. Furthermore, through genome sequencing, we revealed strong correlation of with chloramphenicol resistance, with tetracycline resistance, and with erythromycin resistance.

Conclusion: The introduction of PCV13 into China from 2017 has led to a shift in the dominant composition of pneumococcal strains. There has been a notable rise and spread of multidrug-resistant non-vaccine serotypes among children. Specifically, the non-vaccine serotype 6E, which was not widely reported in China previously, has emerged. To comprehend the resistance mechanisms, it is crucial to further investigate the molecular and genetic characteristics of these non-vaccine serotypes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10806184PMC
http://dx.doi.org/10.3389/fcimb.2023.1332472DOI Listing

Publication Analysis

Top Keywords

non-vaccine serotypes
24
resistance
9
respiratory tracts
8
tracts hospitalized
8
hospitalized children
8
children shenzhen
8
non-vaccine
8
genome sequencing
8
non-vaccine serotype
8
resistance rates
8

Similar Publications

Background: Invasive pneumococcal disease (IPD) remains a significant public health concern, particularly in vulnerable populations such as the elderly. This study focuses on the Faroe Islands, a unique setting for monitoring pneumococcal disease trends due to its high vaccination coverage and geographic isolation.

Objective: To examine the prevalence, trends and serotype distribution of IPD in the Faroe Islands from 2000 to 2023, focusing on the impact of pneumococcal conjugate vaccines (PCVs) on disease incidence and serotype replacement.

View Article and Find Full Text PDF

Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages.

Methods: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the prevalence of nasopharyngeal Streptococcus pneumoniae carriage (NSPC) in infants under two years, focusing on differences by vaccine types and country income levels.
  • A systematic review of 49 articles revealed a highest NSPC prevalence in infants aged 4 to 6 months and 7 to 9 months, particularly elevated in low-income countries.
  • The findings stress the importance of monitoring NSPC trends, especially non-vaccine serotypes, to inform vaccination strategies and reduce pneumococcal disease burden in infants.
View Article and Find Full Text PDF

Streptococcus pneumoniae is the main pathogen that plays a dual role, on the one hand as an asymptomatic carrier in the nasopharyngeal mucosa and on the other hand directly responsible for triggering invasive pneumococcal infections with various important localizations, especially in the pediatric population. Thus, invasive pneumococcal infections represent one of the main causes of mortality and morbidity in children under 5 years of age. Immunization is a key preventive measure against these infections.

View Article and Find Full Text PDF

Changes in population genetic structure of serotype 19A Streptococcus pneumoniae after universal childhood use of the 10-valent pneumococcal conjugate vaccine in Brazil.

Vaccine

December 2024

Instituto Biomédico, Universidade Federal Fluminense, Alameda Barros Terra, s/n, São Domingos, Niterói, RJ 24020-150, Brazil. Electronic address:

Article Synopsis
  • The introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) in Brazil has significantly decreased the prevalence of vaccine serotype-related invasive pneumococcal disease (IPD) in children, but non-vaccine serotypes, particularly 19A, have become more prominent.
  • The study analyzed 32 serotype 19A isolates from a variety of patients, finding that the majority of these isolates came from children and displayed high levels of non-susceptibility to commonly used antibiotics.
  • A significant number of the isolates were multidrug resistant, with a notable shift in genetic lineages, indicating evolving resistance patterns following the introduction of PCV10.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!